

## Neuren reports successful Phase 2 results

### Key points:

- **Neuren successfully completes Phase 2 for its lead candidate Glypromate<sup>®</sup>**
- **Safety of Glypromate<sup>®</sup> confirmed**
- **Planning for Phase 3 trial Q4 2006 on track**

**12 April 2006:** Neuren Pharmaceuticals Ltd (ASX:NEU) has successfully completed its Phase 2 trial of Glypromate<sup>®</sup> involving 33 patients undergoing coronary artery bypass graft surgery.

The study has been referred to the independent Data Safety Monitoring Committee. They have advised the Company that a review of the results has confirmed the drug's clean safety profile as established in the earlier Phase 1 trial.

As previously announced, this now clears the way for an Investigational New Drug application to the US Food and Drug Administration for Neuren to begin a Phase 3 trial planned for later this year.

David Clarke, Chief Executive Officer of Neuren said: "The successful completion of the Phase 2 study is a significant milestone for the Company. It has also been ideal preparation for the larger Phase 3 trial and has enabled us to test systems and processes across a wide range of sites".

The Phase 2 trial was conducted at five sites in Australia and New Zealand including the Alfred Hospital in Melbourne and the Auckland, Mercy, Waikato and Wakefield hospitals in New Zealand.

The Phase 3 trial will involve 520 patients at sites in Australasia, the United States and in Europe. Neuren will be one of very few Australian-listed biotechnology companies entering Phase 3 this year.

The Phase 3 trial is aimed at assessing Glypromate<sup>®</sup>'s effectiveness as a protectant from neurocognitive disturbance following bypass surgery. Impaired cognition is a known complication of these procedures. Over 400,000 patients undergo this surgery each year in the US alone and some loss of brain function has been reported in up to 70% of patients at discharge. There is currently no treatment.

The target market for CABG is estimated at US\$2 billion worldwide and the target market for similar related conditions such as stroke and traumatic brain injury is estimated at US\$4.5 billion worldwide.



**About Neuren Pharmaceuticals**

Neuren Pharmaceuticals (ASX: NEU) is a biotechnology company developing novel therapeutics in the fields of neurotherapy and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has two lead candidates, Glypromate<sup>®</sup> and NNZ-2566, targeting a range of acute and chronic neurological conditions. Neuren has commercial and development partnerships, including Pfizer, the US Army's Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren's website at [www.neurenpharma.com](http://www.neurenpharma.com)

**Contact details**

<b>Company</b>	<b>Media and investor relations</b>
David Clarke CEO of Neuren T: 1800 259 181 (Australia) T: +64 9 3 367 7167 ext 82308 (New Zealand) M: +64 21 988 052  Dr Robin Congreve Chairman M: +64 21 673 935	Rebecca Piercy Buchan Consulting T: +61 2 9237 2800 M: +61 422 916 422